Xencor, Inc. (XNCR)
Stock Price Chart
Key Info
| Market Cap | 2.26B |
| Revenue (ttm) | 70.75M |
| Net Income (ttm) | -80.23M |
| Shares Out | 57.24M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $39.48 |
| Previous Close | $39.49 |
| Change ($) | -0.01 |
| Change (%) | -0.03% |
| Day's Open | 39.92 |
| Day's Range | 38.99 - 40.44 |
| Day's Volume | 180,662 |
| 52-Week Range | 19.35 - 43.90 |
More Stats
| Market Cap | 2.26B |
| Enterprise Value | 1.68B |
| Earnings Date (est) | Nov 10, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 57.24M |
| Float | 56.91M |
| EPS (basic) | -1.40 |
| EPS (diluted) | -1.41 |
| FCF / Share | -0.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 3.84M |
| Short Ratio | 8.99 |
| Short % of Float | 6.75% |
| Beta | 0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 31.94 |
| PB Ratio | 3.91 |
| Revenue | 70.75M |
| Operating Income | -91.23M |
| Net Income | -80.23M |
| Free Cash Flow | -52.46M |
| Net Cash | 576.54M |
| Net Cash / Share | 10.07 |
| Gross Margin | 53.87% |
| Operating Margin | -128.94% |
| Profit Margin | -113.40% |
| FCF Margin | -74.14% |
| ROA | -8.56% |
| ROE | -13.61% |
| ROIC | -15.40% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157 | 40.60 | 46.15 | 109 | 27.76 | 9.52 | 10.17 | 9.52 | 6.85 |
| Revenue Growth | 285.93% | -12.02% | -57.67% | 292.7% | 191.62% | -6.41% | 6.8% | 39.06% | - |
| Gross Profit | 157 | 40.60 | 46.15 | 109 | 27.76 | 9.52 | 10.17 | 9.52 | 6.85 |
| Operating Income | 13.82 | -79.37 | -43.12 | 44.04 | -18.34 | -16.46 | -10.52 | -6.23 | -9.45 |
| Net Income | 26.88 | -70.41 | -38.49 | 45.13 | -17.59 | -16.42 | -60.26 | -8.59 | -11.20 |
| Shares Outstanding | 56.53 | 53.94 | 46.82 | 41.27 | 39.02 | 31.39 | 2.47 | 0.07 | 0.07 |
| Earnings Per Share | 0.46 | -1.31 | -0.82 | 1.07 | -0.45 | -0.52 | -3.85 | -118.86 | -154.95 |
| Operating Cash Flow | 64.37 | -79.76 | -33.60 | 95.24 | 26.67 | -21.35 | -5.45 | -11.05 | -1.09 |
| Capital Expenditures | -7.35 | -7.20 | -5.31 | -1.51 | -1.92 | -0.78 | -0.12 | 0.06 | 0.08 |
| Free Cash Flow | 57.02 | -86.96 | -38.91 | 93.73 | 24.75 | -22.13 | -5.57 | -11.00 | -1.01 |
| Cash & Equivalents | 530 | 294 | 224 | 130 | 96.43 | 54.65 | 77.98 | 2.31 | - |
| Total Debt | 10.73 | - | - | - | - | - | 0.01 | 20.94 | - |
| Net Cash / Debt | 519 | 294 | 224 | 130 | 96.43 | 54.65 | 77.97 | -18.63 | - |
| Assets | 670 | 577 | 390 | 429 | 207 | 67.82 | 87.32 | 11.66 | - |
| Liabilities | 77.05 | 55.05 | 73.74 | 115 | 44.48 | 8.53 | 13.78 | 31.16 | - |
| Book Value | 593 | 522 | 316 | 314 | 162 | 59.29 | 73.53 | -166 | - |
Company Profile
Company Details
| Full Name | Xencor, Inc. |
| Country | United States |
| Employees | 166 |
| CEO | Bassil I. Dahiyat |
Stock Information
| Ticker Symbol | XNCR |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: XNCR |
| IPO Date | December 3, 2013 |
Description
Xencor, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.